Latest News

Breath Therapeutics cashes in €43,5m

Pari Pharma spin off Breath Therapeutics (Frankfurt/Munich) combines immunosuppressant drugs with advanced nebulisation technology to treat the rare lung disease BOS, © fotolia.com/magicmine


by tg

Inhaled lung therapeutics specialist Breath Therapeutics Holding BV closed a Series A financing led by Gimv and Sofinnova. 

Gilde Healthcare acted as co-investor for Breath Therapeutics’ orphan drug programme. The spin-off company of the Munich-headquartered nebulisation expert PARI Pharma, part of the global Pari Group, said it will use the funds for financing of Phase III trials and US/EU commercialisation.

Breath Therapeutics’ lead programme is a first-in-class therapeutic/med-tech device combination to treat the Bronchiolitis Obliterans Syndrome (BOS), a life-threatening disease that occurs after 65% of lung transplantations. The company managed to administer a liposomal formulation of the immunesuppressant drug cyclosporin A, using an optimised version of PARI Pharma’s eFlow nebulisator, which can monitor therapy compliance, online.

Breath Therapeutics founders and managers have a well-documented track record in immunesuppressant drug development and nebulisation technology: Jens Stegemann (CEO), Anne Burger (CFO), Gerhard Boerner (CSO), Oliver Denk (COO). Graziano Seghezzi, partner at Sofinnova, Karl Nägler, partner at Gimv, and Arthur Franken, partner at Gilde Healthcare will be on the board of directors.

Evotec expanding at Milton Park campus

According to Evotec, adding a new building by the end of the year, will bring together all the key functions for small molecule discovery and up to...

EU COVID-19 antibody ready for clinical trials

CORAT Therapeutics reports the start of production of the first batch of  the therapeutic human COVID-19 antibody COR-101 for Phase I testing....

Merry Christmas and a Happy New Year

Janssen presents one-shot COVID-19 vaccine data

Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine...

Vifor Pharma in US$100m licence deal with Cara Therapeutics

Under the licence deal with the US company Cara Therapeutics Inc., Swiss Vifor Pharma has acquired the US commercialisation rights for intravenous...

Vifor Pharma inks $340m deal with Angion Biomedica Inc.

Under the deal, Zurich-based Vifor Pharma will pay $30m upfront, make a $30m equity investment in Angion Biomedica and hold out the prospect of...

Drug set to rescue COVID-19 patients at ICUs

Initial data from an US expanded access  (EA) use of RLF-100™ (aviptadil) in 90 ICU patients with critical COVID-19 and severe comorbidities...